The global clinical microbiology market size was valued at USD 9.1 billion in 2016 and is expected to develop at a CAGR of 6.7% over the forecast period. Constantly rising incidence of infectious diseases is driving market growth.
Infectious diseases are primarily diagnosed using clinical tests. According to the Centers for Disease Control and Prevention (CDC), around 9,421 new cases of tuberculosis, 51,455 new cases of salmonella, 33,461 new cases of Lyme disease, and 433 new cases of meningococcal disease were registered in U.S. in 2014.
Similarly, according to the American Cancer Society, around 1,688,780 new cases of cancer were diagnosed in U.S. in 2017. Thus, high prevalence of diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth in future. Sudden outbreaks of Ebola, Zika, and other contagious pathogens are also contributing to rising prevalence of infectious diseases.
As per an article published in the Journal of Clinical Microbiology, there is a shortage of trained and skilled professionals in medical and microbiological laboratories for processing and interpreting samples and specimens. Moreover, there has been a steep decline in the number of medical laboratory training programs and students graduating from such programs in U.S.
Lack of trained graduates and training programs is an issue particularly in developing countries, where demand for skilled professionals is rapidly increasing. However, entry of automated systems in the market is going to replace manually-operated conventional platforms in future, thereby reducing the impact of lack of skilled professionals.
Reagents accounted for the largest revenue share in the global clinical microbiology market. The segment includes products such as solutions, primers, master mixes, and kits used in various diagnostic assays. Reagents currently captures the largest revenue share, with more than 60% attributed to repeat purchase driven by need for new set of reagents for new tests.
The segment is expected to remain dominant throughout the forecast period. Factors such as higher cost of specialized kits and constant repeat purchase are expected to drive the segment over the forecast period. The market is witnessing rising investments in research and development (R&D). Almost all analytical and therapeutic research projects demand reagents and chemicals, thereby driving penetration of reagents.
Laboratory instruments comprise incubators, gram strainers, bacterial colony counters, autoclave sterilizers, petri dish fillers, and culture systems. Automated culture systems dominated the global laboratory instruments segment with more than 30% share in 2016.
The microbiology analyzers segment comprises instruments used in molecular diagnostics, mass spectrometry, and microscopes. Microscopes held the largest share owing to wider applicability and rising demand. The molecular diagnostic instruments segment, on the other hand, is expected to exhibit the fastest growth rate over the forecast period. This growth can be attributed to increasing significance of molecular diagnosis in early detection of cancer and infectious diseases.
Increasing levels of air pollution with growing industrialization is resulting in rapid escalation in prevalence of respiratory diseases. Also, among all infections, respiratory diseases spread rapidly owing to easy transfer of contagious pathogens. Thus, the segment is expected to show significant growth over the forecast period. Furthermore, prevalence of infectious diseases is high in developed as well as developing countries.
In addition, according to a few investigations recently published in the Journal of the American Medical Association, chronic respiratory diseases were responsible for about 1 in 15 deaths in 2015. Approximately USD 132 billion of healthcare spending was associated with these diseases in 2013. Biopsy, blood tests, and bronchoscopy are the most commonly used diagnostic tools for respiratory diseases. Therefore, rising incidence of chronic respiratory diseases is boosting market growth.
North America accounted for the largest revenue share in 2016 and was closely followed by Europe. Highly developed industrial and healthcare sectors in U.S. are fueling adoption of advanced clinical diagnostic techniques. In addition, stringent regulatory framework and presence of leading players are augmenting regional market growth.
Asia Pacific is expected to be the fastest growing region from 2016 to 2024. Japan is one of the leading countries with strong technological developments and high usage of microbial testing for various applications. China is another significant market contributing to regional growth.
Booming medical tourism industry is expected to spur demand for microbial diagnostic and monitoring tests in Asian countries such as India, China, Thailand, and Malaysia. Furthermore, availability of skilled labor at affordable cost and advanced manufacturing infrastructure are resulting in manufacturing facilities of major pharmaceutical and medical device makers shifting to Asia. This is boosting regional market expansion.
The market is presently dominated by a few key participants such as bioMerieux S.A.; Cepheid Inc.; Danaher Corporation; and Bruker Corporation. Other prominent players operating in the market include but are not limited to Becton Dickinson & Company; Hologic Inc.; Roche Diagnostics; and Alere Inc. Introduction of automated systems and innovative designs is expected to intensify the competition by changing market dynamics over the forecast period.
Report Attribute |
Details |
Market size value in 2020 |
USD 12.4 billion |
Revenue forecast in 2025 |
USD 16.7 billion |
Growth Rate |
CAGR of 6.7% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Million & CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, region |
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Brazil; Mexico; & South Africa |
Key companies profiled |
bioMerieux S.A.; Cepheid Inc.; Danaher Corporation; Bruker Corporation; Becton Dickinson & Company; Hologic Inc.; Roche Diagnostics; Alere Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global clinical microbiology market report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Laboratory Instruments
Incubators
Gram Stainers
Bacterial Colony Counters
Autoclave Sterilizers
Petri Dish Fillers
Automated Culture Systems
Microbiology Analyzers
Molecular Diagnostic Instruments
Microscopes
Mass Spectrometers
Reagents
Application Outlook (Revenue, USD Million, 2014 - 2025)
Respiratory Diseases
Bloodstream Infections
Gastrointestinal Diseases
Sexually Transmitted Diseases
Urinary Tract Infections
Periodontal Diseases
Other Diseases
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
China
India
Japan
Latin America
Mexico
Brazil
Middle East & Africa
South Africa
b. The global clinical microbiology market size was estimated at USD 11.6 billion in 2019 and is expected to reach USD 12.4 billion in 2020.
b. The global clinical microbiology market is expected to grow at a compound annual growth rate of 6.7% from 2017 to 2025 to reach USD 16.7 billion by 2025.
b. North America dominated the clinical microbiology market with a share of 40.3% in 2019. This is attributable to highly developed industrial and healthcare sectors in the U.S. that are fueling the adoption of advanced clinical diagnostic techniques.
b. Some key players operating in the clinical microbiology market include bioMerieux S.A.; Cepheid Inc.; Danaher Corporation; Bruker Corporation; Becton Dickinson & Company; Hologic Inc.; Roche Diagnostics; and Alere Inc.
b. Key factors that are driving the market growth include rising demand for automation and increasing the prevalence of infectious and chronic diseases.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.